Kinzbio
Kinzbio is a biotechnology company specializing in phage-based precision antimicrobials to combat antibiotic-resistant infections. Their platform delivers personalized, pharmaceutical-grade therapies within 5-15 days, tailored to specific bacterial infections. They also develop preventative solutions for hospitals and ICUs. Kinzbio differentiates itself through a combination of patents, proprietary databases, biobanks, and AI-driven software for phage optimization. Their approach is personalized, adaptable, fast, environmentally friendly, and highly specific in targeting harmful bacteria while preserving beneficial microbes. Kinzbio has successfully treated patients in Uruguay for conditions like ventilator-associated pneumonia and prosthetic joint infections, demonstrating complete bacterial eradication. The company has received support from incubators and accelerators like INCATE and Eretz.Bio, and has established a regulatory framework in collaboration with Uruguay's Ministry of Health, aligning with international standards. They are exploring new markets in Brazil, Europe, and Colombia and actively seek collaborations with pharma leaders, clinical organizations, and funding agencies to accelerate their platform development.
Kinzbio
Kinzbio is a biotechnology company specializing in phage-based precision antimicrobials to combat antibiotic-resistant infections. Their platform delivers personalized, pharmaceutical-grade therapies within 5-15 days, tailored to specific bacterial infections. They also develop preventative solutions for hospitals and ICUs. Kinzbio differentiates itself through a combination of patents, proprietary databases, biobanks, and AI-driven software for phage optimization. Their approach is personalized, adaptable, fast, environmentally friendly, and highly specific in targeting harmful bacteria while preserving beneficial microbes. Kinzbio has successfully treated patients in Uruguay for conditions like ventilator-associated pneumonia and prosthetic joint infections, demonstrating complete bacterial eradication. The company has received support from incubators and accelerators like INCATE and Eretz.Bio, and has established a regulatory framework in collaboration with Uruguay's Ministry of Health, aligning with international standards. They are exploring new markets in Brazil, Europe, and Colombia and actively seek collaborations with pharma leaders, clinical organizations, and funding agencies to accelerate their platform development.